Moderate to Severe Atopic Dermatitis Care in Practice: Disease Burden and Integrated Care Pathways

Key Takeaways

• Persistent care gaps include under-recognition of severity, delayed escalation beyond topical therapy, and inconsistent use of validated metrics to guide treat-to-target decisions.
• Biologic therapy adoption is expanding due to improved efficacy–safety profiles and steroid-sparing potential, particularly for patients with refractory pruritus and extensive skin involvement.
• Health system factors such as prior authorization, specialty pharmacy workflows, and formulary restrictions materially shape time-to-treatment and continuity of biologic use.
• Operationalizing biologics benefits from standardized pathways covering baseline evaluation, vaccination and infection risk review, follow-up cadence, and objective response assessment to support timely switching or optimization.